HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $20
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $15 to $20.
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $15 to $20.